Group 1: Event Details - Shenzhen Huashengchang Technology Industry Co., Ltd. will participate in the "Communicating Value, Creating a Good Ecosystem" online collective reception day for investors on November 30, 2021 [2] - The event will be held from 14:00 to 17:00, with the interactive session between the company and investors scheduled from 15:30 to 17:00 [2] - Investors can join the event via the "Panjing Roadshow" website or the WeChat public account "Panjing Finance" [2] Group 2: Company Commitment - The company and its board members guarantee that the information disclosed is true, accurate, and complete, with no false records or misleading statements [2] - The chairman, board secretary, and financial director will communicate with investors through online text exchanges [2] Group 3: Invitation to Investors - The company encourages all investors to actively participate in the event [2]

Financial Performance - The company's revenue for Q3 2021 was ¥194,696,356.01, representing a 1.28% increase year-over-year, but a 30.19% decrease for the year-to-date period at ¥551,730,782.54[4] - Net profit attributable to shareholders for Q3 2021 was ¥44,819,165.75, down 7.16% year-over-year, and down 58.53% year-to-date at ¥130,724,287.03[4] - The basic earnings per share for Q3 2021 was ¥0.34, a decrease of 6.63% year-over-year, and down 63.16% year-to-date[5] - The total operating revenue for the period was CNY 551,730,782.54, a decrease of 30.2% compared to CNY 790,363,549.92 in the previous period[20] - The company reported a decrease in diluted earnings per share to ¥0.34, down 6.63% year-over-year, and down 63.16% year-to-date[5] - The net profit for Q3 2021 was CNY 130,781,983.82, a decrease of 58.6% compared to CNY 315,314,682.29 in the same period last year[22] - The total revenue from operating activities was CNY 638,516,907.33, down 26.7% from CNY 871,712,719.77 in the previous year[25] - The company reported a total comprehensive income of CNY 130,766,302.70, compared to CNY 315,165,522.02 in the prior year[23] - Basic and diluted earnings per share were both CNY 0.98, down from CNY 2.66 in the same quarter last year[23] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥16,136,691.01, reflecting a significant decline of 94.39%[4] - The company's cash and cash equivalents as of September 30, 2021, were CNY 369,727,073.40, compared to CNY 366,837,779.81 at the end of 2020, showing a marginal increase[16] - The cash flow from operating activities showed a net inflow of CNY 16,136,691.01, significantly lower than CNY 287,668,675.20 in Q3 2020[26] - The cash and cash equivalents at the end of the period were CNY 369,727,073.40, a decrease from CNY 627,992,308.60 at the end of Q3 2020[27] - The cash flow from investing activities generated a net inflow of CNY 148,187,398.39, contrasting with a net outflow of CNY 227,850,409.29 in Q3 2020[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,176,518,263.88, a decrease of 1.21% compared to the end of the previous year[5] - The total equity attributable to shareholders was ¥1,043,466,268.04, a decrease of 1.35% from the end of the previous year[5] - The total liabilities were CNY 132,715,851.87, showing a slight decrease from CNY 132,941,532.96 in the previous period[18] - The total assets as of September 30, 2021, were CNY 1,176,518,263.88, a decrease from CNY 1,190,985,051.58 at the end of 2020[19] - The company's net profit for the period was not explicitly stated, but the retained earnings decreased to CNY 286,956,552.45 from CNY 302,899,005.42, a decline of 5.3%[19] Operational Insights - The decline in revenue was primarily attributed to a decrease in sales of pandemic prevention products compared to the previous year, which had seen a significant increase due to COVID-19[9] - Total operating costs amounted to CNY 417,478,695.29, which is a slight decrease of 4.8% from CNY 434,939,278.83 in the previous period[20] - The total operating expenses were CNY 622,380,216.32, an increase from CNY 584,044,044.57 in the same quarter last year[26] - The company reported a decrease in sales revenue from CNY 581,914,813.56 in Q3 2021 compared to CNY 821,342,805.95 in Q3 2020[25] Strategic Developments - The company has obtained EU CE certification and UK MHRA registration for its real-time fluorescence quantitative PCR analyzer product, enhancing its market credibility[14] - The company signed a cooperation agreement with Southern University of Science and Technology to establish a joint laboratory, indicating a strategic focus on R&D collaboration[14] Other Considerations - The company incurred a foreign exchange loss of CNY 15,681.12 in Q3 2021, compared to a loss of CNY 149,160.27 in the previous year[23] - The company has not undergone an audit for the third quarter report, which may affect investor confidence[32] - The company is adapting to new accounting policies, which may impact future financial reporting[32]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 357,034,426.53, a decrease of 40.31% compared to CNY 598,131,438.35 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was CNY 85,905,121.28, down 67.82% from CNY 266,923,749.48 year-on-year[22]. - The net cash flow from operating activities was CNY 24,635,777.70, a significant decline of 91.09% compared to CNY 276,371,725.93 in the previous year[22]. - Basic earnings per share decreased by 73.33% to CNY 0.64 from CNY 2.40 in the same period last year[22]. - The total assets at the end of the reporting period were CNY 1,166,377,583.69, a decrease of 2.07% from CNY 1,190,985,051.58 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were CNY 997,691,289.56, down 5.68% from CNY 1,057,765,071.43 at the end of the previous year[22]. - The weighted average return on net assets was 7.80%, a decrease of 31.56% compared to 39.36% in the same period last year[22]. - The net profit after deducting non-recurring gains and losses was CNY 77,909,920.53, down 69.53% from CNY 255,701,033.22 year-on-year[22]. - The gross profit margin for the reporting period was impacted by a decrease in sales volume, resulting in a net profit attributable to shareholders dropping by 67.82%[71]. - The company's revenue for the reporting period was CNY 357,034,426.53, a decrease of 40.31% compared to CNY 598,131,438.35 in the same period last year, primarily due to a significant drop in sales of pandemic prevention products[71]. Product Development and Innovation - The company has over 500 models of DIY electrical and power products, maintaining a stable and rapid growth in the market, particularly in portable measurement instruments[32]. - The newly developed DT-7760 energy quality and management instrument will be launched soon, featuring advanced measurement capabilities and multiple communication interfaces[33]. - The company has developed a professional electrical safety testing instrument in collaboration with a high-end UK brand, capable of testing various safety indicators[37]. - The company has a comprehensive capability in infrared thermal imaging, with self-developed non-cooling infrared detector technology and mass production capabilities[38]. - The company has developed a series of thermal imaging products, including the "Thermal Imaging+" series, which combines thermal imaging modules with various measurement products, establishing a significant technological advantage and barrier in the domestic market[40]. - The infrared temperature measurement technology developed by the company boasts a measurement speed of milliseconds and an accuracy of up to 1%, with a temperature range from -50°C to over 2000°C, applicable in various industries[44]. - The company has developed strong relationships with major brand clients, leveraging its design and quality control capabilities to enhance product competitiveness[68]. - The company is committed to optimizing existing products and developing new technologies in the medical diagnostics field, including plans for antigen and antibody reagent production[53]. Market Performance and Strategy - The company achieved operating revenue of 357.03 million yuan in the first half of 2021, with a net profit attributable to shareholders of 85.91 million yuan, representing a 46.30% increase in sales revenue of non-epidemic products compared to the same period last year[30]. - The overall operating revenue increased by 51.65% compared to the first half of 2019, and the net profit attributable to shareholders grew by 80.11% compared to the same period in 2019[30]. - The company is actively expanding its market presence in environmental monitoring, with a focus on supporting national carbon neutrality goals by developing products for air quality monitoring and emissions analysis[49]. - The company is expanding its operational footprint with multiple facilities across different regions, including a 1,330.00 million CNY factory in Yangguang Industrial Zone[129]. - The company is actively expanding its overseas e-commerce sales channels, integrating online and offline marketing strategies on platforms like Amazon and Alibaba[56]. - The company plans to enhance its innovation capabilities and increase market share in emerging countries to mitigate risks from international trade policies and exchange rate fluctuations[96]. Financial Management and Investments - The company reported a significant increase in cash flow from investing activities, with a net amount of CNY 257,793,289.87, up 2,661.02% due to increased cash recovered from financial products[71]. - The total amount of entrusted financial management funds reached 54,500 million, with 36,500 million from raised funds and 18,000 million from self-owned funds[133]. - The company has maintained a healthy liquidity position with no overdue receivables reported[133]. - The company did not engage in any securities or derivative investments during the reporting period[92][93]. - The company has no significant guarantees during the reporting period, reflecting a conservative financial approach[131]. Corporate Social Responsibility - The company donated a total of 1 million yuan (approximately $154,000) in materials and cash to support poverty alleviation and rural revitalization efforts in Guangdong Province[109]. - The company donated 300 sets of 8806H infrared thermometers to the Guangdong Province Zhong Nanshan Medical Foundation in March 2021, demonstrating its commitment to social responsibility[109]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and forecasts[5]. - The company acknowledges the competitive risks in the instrument and meter industry and aims to enhance product quality and management efficiency to maintain competitiveness[100]. - The company is facing risks from rising raw material prices and plans to optimize supply chain resources and improve cost control to mitigate these risks[99]. Shareholder Information - The total number of shares outstanding is 133,333,400, with 75% being restricted shares[138]. - Major shareholders include Yuan Jianmin with 54.00% ownership and Che Haixia with 7.50% ownership[140]. - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[142]. Compliance and Governance - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial statements accurately reflect its financial position and operating results[198]. - The company has evaluated its ability to continue as a going concern for the next 12 months and found no significant doubts regarding its sustainability[196]. - The company did not report any changes in accounting policies or prior period error corrections during the current reporting period[179].

Financial Performance - The company's operating revenue for 2020 was CNY 962,660,824.57, representing a 106.78% increase compared to CNY 465,545,558.22 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 337,558,995.59, a significant increase of 271.10% from CNY 90,960,682.35 in 2019[16] - The net profit after deducting non-recurring gains and losses was CNY 323,190,536.67, up 274.13% from CNY 86,385,197.30 in the previous year[16] - The net cash flow from operating activities reached CNY 295,572,015.67, an increase of 152.12% compared to CNY 117,232,452.74 in 2019[16] - Basic earnings per share for 2020 were CNY 2.76, a 203.30% increase from CNY 0.91 in 2019[16] - The operating profit reached CNY 393.79 million, up 274.36% compared to the previous year[53] - The company reported a revenue of 428,225,683.85 yuan for the year 2020, with a significant impact of 9,651,462.73 yuan due to the new revenue recognition standards[141] Assets and Liabilities - The total assets at the end of 2020 amounted to CNY 1,190,985,051.58, reflecting a 151.98% increase from CNY 472,654,052.22 at the end of 2019[18] - The net assets attributable to shareholders were CNY 1,057,765,071.43, up 169.26% from CNY 392,837,530.01 in 2019[18] - As of December 31, 2020, the total assets amounted to RMB 1,190.9851 million, with total liabilities of RMB 132.9415 million, resulting in a debt-to-asset ratio of 11.16%[181] - Total assets increased significantly, with cash and cash equivalents rising by 56.67% compared to the beginning of the year[84] Revenue Breakdown - Revenue from infrared products was CNY 123.47 million, accounting for 12.83% of total revenue, with a growth of 544.71% year-on-year[54] - Revenue from human body temperature measurement products was CNY 350.72 million, representing 36.43% of total revenue, with a staggering increase of 4,926.22% year-on-year[54] - Non-epidemic product revenue was CNY 488.47 million, making up 50.74% of total revenue, which is an 11.07% increase from the previous year[55] Research and Development - The company emphasizes a strong focus on R&D, utilizing market research and customer feedback to drive product development[32] - R&D expenses amounted to ¥47,167,610.98, reflecting a 26.45% increase from ¥37,300,630.49 in 2019[74] - The company’s R&D personnel increased by 22.31% to 148, while the R&D expenditure as a percentage of revenue decreased to 4.90% from 8.01%[76] Dividend Policy - The company plans to distribute a cash dividend of CNY 11 per 10 shares, based on a total of 13,333,340 shares[5] - The cash dividend payout ratio for 2020 is 81.37% of the net profit attributable to shareholders[129] - The proposed cash dividend for 2020 is RMB 11 per 10 shares, totaling RMB 146,666,740 (including tax) based on a total share capital of 13,333.34 million shares[131] Risks and Challenges - The company faces risks from the COVID-19 pandemic, which may reduce demand for infrared temperature measurement products, and plans to diversify its product offerings[113] - Approximately 50% of the company's foreign sales revenue comes from the U.S., exposing it to risks from U.S.-China trade tensions[114] - The company is experiencing rising labor and rental costs, which may impact its operating performance[117] Corporate Governance - The company has established a comprehensive corporate governance structure, ensuring compliance with laws and regulations during shareholder meetings[166] - The company has committed to measures to compensate for the dilution of immediate returns for shareholders, which are being fulfilled as planned[133] - The company has not reported any non-operating fund occupation by controlling shareholders or their affiliates during the reporting period[135] Market and Product Development - The company has developed a comprehensive range of measurement and testing instruments across various sectors including power, electronics, and healthcare[26] - The company launched several new products, including smart infrared temperature inspection gates and AI temperature attendance machines, to meet diverse customer needs[56] - The company operates under an ODM model for international markets while actively promoting its own brand "CEM" in emerging markets like Russia and India[36] Investment and Financing - The company completed its initial public offering, issuing 33.33 million shares at a price of CNY 14.89 per share, raising a total of CNY 49.63 million[57] - The company is actively advancing its investment projects, including the construction of a production base in Bazhong, with a loan of up to CNY 50 million allocated for this purpose[60] - The total amount of funds raised by the company was 496.33 million CNY, with a net amount of 454.27 million CNY after deducting issuance costs of 42.07 million CNY[97] Employee and Social Responsibility - The company emphasizes employee rights and development, implementing a detailed human resources management system[167] - The company donated 200 non-contact infrared thermometers and 200 forehead thermometers to local charities during the COVID-19 pandemic, along with 500,000 RMB in materials and cash[169] Shareholder Information - The largest shareholder, Yuan Jianmin, holds 54.00% of the shares, while the second-largest shareholder, Che Haixia, holds 7.50%[184] - The company has not undergone any changes in its controlling shareholder during the reporting period[186] - The actual controller, Yuan Jianmin, is also the chairman and general manager of the company[187]

Financial Performance - The company's operating revenue for Q1 2021 was ¥164,423,521.31, a decrease of 21.59% compared to ¥209,689,709.87 in the same period last year[8]. - Net profit attributable to shareholders was ¥40,523,552.79, down 54.77% from ¥89,588,268.95 year-on-year[8]. - Basic and diluted earnings per share were both ¥0.30, representing a decrease of 66.67% from ¥0.90 in the same period last year[8]. - Operating profit decreased by 55.93% attributed to reduced sales revenue and declining gross margin[17]. - Net profit decreased by 54.78% primarily due to decreased sales revenue and lower gross margin[17]. - Total operating revenue for Q1 2021 was CNY 164,423,521.31, a decrease from CNY 209,689,709.87 in the previous period[45]. - Net profit for Q1 2021 was CNY 40,546,036.69, down from CNY 89,662,359.20 in the same period last year[47]. - The total comprehensive income for the period was CNY 40,474,612.45, compared to CNY 89,441,263.93 in the previous year[48]. Cash Flow - The net cash flow from operating activities was ¥5,316,218.05, a significant decline of 97.05% compared to ¥179,988,497.13 in the previous year[8]. - Cash flow from operating activities decreased by 97.05% mainly due to reduced customer prepayments and increased inventory[18]. - The cash flow from operating activities was impacted by increased payments to employees, which rose to CNY 39,058,760.94 from CNY 30,892,065.03, an increase of approximately 26.5%[58]. - Net cash flow from operating activities decreased significantly to CNY 7,401,309.44 from CNY 143,843,982.33, a decline of about 94.8%[58]. - Cash inflow from investment activities totaled CNY 447,639,863.02, while cash outflow was CNY 362,556,961.70, resulting in a net cash flow of CNY 85,082,901.32[59]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,233,950,732.45, an increase of 3.61% from ¥1,190,985,051.58 at the end of the previous year[8]. - The company's total assets as of March 31, 2021, were CNY 1,225,556,492.02, compared to CNY 1,174,757,720.81 at the end of 2020[42]. - Total liabilities rose to CNY 140,719,097.40 from CNY 127,365,320.98, with current liabilities decreasing to CNY 102,289,259.25 from CNY 121,980,673.07[43]. - The company's total liabilities amounted to ¥135,076,075.81, slightly increasing from ¥132,941,532.96 at the end of 2020[38]. - Total liabilities increased from CNY 132,941,532.96 to CNY 172,982,714.26, reflecting an adjustment of CNY 40,041,181.30[63]. Shareholder Equity - Net assets attributable to shareholders increased by 3.86% to ¥1,098,573,725.56 from ¥1,057,765,071.43 at the end of the previous year[8]. - The total equity attributable to shareholders of the parent company was CNY 1,098,573,725.56, up from CNY 1,057,765,071.43[42]. - The total equity remained unchanged at CNY 1,058,043,518.62, indicating stability in the company's ownership structure[63]. Government Support and Investments - The company received government subsidies amounting to ¥2,300,243.40 during the reporting period[9]. - The company reported a fair value change and investment income from trading financial assets of ¥2,549,780.81[9]. - The company received CNY 445,000,000.00 from investment recoveries during the reporting period[58]. Operational Insights - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[31]. - Research and development expenses for Q1 2021 were CNY 10,162,534.49, slightly down from CNY 10,849,011.26 in the previous year[46]. - The company engaged in investor communications to discuss operational performance and future strategies, including a call with Athena Capital on January 11, 2021[30]. Other Financial Metrics - Financial expenses decreased by 67.80% mainly due to exchange rate fluctuations and increased interest income[17]. - The company reported a decrease in other comprehensive income, with a net amount of -CNY 71,424.24 compared to -CNY 221,095.27 in the previous period[47]. - The company has not engaged in any securities or derivative investments during the reporting period[20][21].

证券代码：002980 证券简称：华盛昌 公告编号：2020-054 深圳市华盛昌科技实业股份有限公司 关于参加 2020 深圳辖区"诚实守信，做受尊重的上市公司" | --- | |----------------------------------------------------------------| | 上市公司投资者网上集体接待日活动的公告 | | 本公司及公司全体董事会成员保证信息披露的内容真实、准确、完整， | | 没有虚假记载、误导性陈述或重大遗漏。 | 为进一步加强与投资者的互动交流工作，深圳市华盛昌科技实业股份有限公 司（以下简称"公司"）将参加由深圳上市公司协会、深圳市全景网络有限公司 共同举办的"诚实守信，做受尊重的上市公司"——2020深圳辖区上市公司投资 者网上集体接待日活动，现将有关事项公告如下： 本次集体接待日活动将在深圳市全景网络有限公司提供的网上平台，采取网 络远程的方式举行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net/） 或关注微信公众号：全景财经，参与公司本次投资者集体接待日活动，活动时间 为2020年12月8日9:00至17:00， ...

Financial Performance - Operating revenue for the current period reached CNY 192,232,111.57, an increase of 81.67% year-on-year[8] - Net profit attributable to shareholders increased by 85.17% to CNY 48,275,449.98 compared to the same period last year[8] - The company reported a net profit of CNY 315,199,199.46 for the year-to-date, an increase of 327.29% compared to the same period last year[8] - Total revenue for the third quarter reached ¥790,363,549.92, a 131.78% increase compared to ¥340,996,042.59 in the previous period, primarily driven by increased sales of epidemic prevention products[18] - Net profit for the third quarter was ¥315,314,682.29, representing a 327.32% increase from ¥73,789,222.87 in the same period last year, attributed to significant revenue growth[18] - The total profit for the quarter was CNY 368.68 million, significantly higher than CNY 85.26 million in the previous year, indicating robust financial performance[62] Assets and Liabilities - Total assets increased by 144.48% to CNY 1,155,554,721.49 compared to the end of the previous year[8] - Total liabilities increased to CNY 128,993,043.86 from CNY 82,841,932.60, indicating a rise in financial obligations[49] - The total current assets reached ¥1.11 billion, up from ¥440.33 million in the previous year, indicating a significant increase of 151.5%[43] - The company's inventory increased by 42.21% to ¥170,568,314.91, driven by a significant rise in sales revenue[17] - The company reported inventory of CNY 119,943,105.87, indicating a significant asset base for operations[76] Shareholder Information - Net assets attributable to shareholders increased by 163.56% to CNY 1,035,350,017.02 compared to the end of the previous year[8] - The number of ordinary shareholders at the end of the reporting period was 24,358[12] - The largest shareholder, Yuan Jianmin, holds 54.00% of the shares, totaling 72,000,000 shares[12] Cash Flow - Cash flow from operating activities decreased by 72.20% to CNY 11,296,949.27 compared to the same period last year[8] - Cash flow from operating activities increased by 193.92% to ¥287,668,675.20, due to timely collection of payments[18] - The ending balance of cash and cash equivalents was CNY 627,992,308.60, up from CNY 214,531,875.63 at the end of Q3 2019, marking an increase of about 193.5%[70] - Net cash flow from operating activities reached CNY 287,668,675.20, compared to CNY 97,874,642.04 in the same period last year, indicating a year-over-year increase of about 194.5%[69] Research and Development - Research and development expenses rose by 41.39% to ¥34,019,633.43, reflecting increased investment in new product development[18] - Research and development expenses for the quarter were CNY 12,642,370.26, compared to CNY 9,696,559.96 in the previous year, highlighting a focus on innovation[52] - Research and development expenses for Q3 2020 amounted to CNY 12,685,692.61, compared to CNY 9,719,527.28 in the previous year, indicating a growth of 30.2%[56] Earnings Per Share - Basic earnings per share rose by 38.46% to CNY 0.36[8] - Basic and diluted earnings per share for Q3 2020 were both CNY 0.36, compared to CNY 0.26 in the previous year, reflecting a growth of 38.5%[54] - Basic earnings per share rose to CNY 2.66, compared to CNY 0.74 in the same quarter last year, showcasing improved profitability[62] Financial Management - The weighted average return on equity was 4.24%, a decrease of 2.96% compared to the previous year[8] - The company reported a financial expense of CNY 2.42 million, a decrease from CNY 5.21 million, suggesting improved cost management[61] - Other income increased to CNY 13.03 million from CNY 4.39 million, contributing positively to the overall financial results[61] Investment Activities - The company raised ¥338,873,205.60 through its initial public offering, marking a 100% increase in financing activities[18] - The company has invested ¥21.5 million in wealth management products, with no overdue amounts reported[33] - The company has not made any securities or derivative investments during the reporting period[26][27] Commitments and Future Plans - The company plans to use up to ¥400 million of idle funds for cash management, with ¥215 million already utilized[22] - The company has not changed its fundraising project commitments, with a total commitment of RMB 45.43 million[31] - The company has not reported any significant changes in expected operating performance for the year 2020[32]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥598,131,438.35, representing a 154.33% increase compared to ¥235,181,288.08 in the same period last year[16]. - The net profit attributable to shareholders was ¥266,923,749.48, a significant increase of 459.64% from ¥47,695,679.54 in the previous year[16]. - The net cash flow from operating activities reached ¥276,371,725.93, up 382.83% from ¥57,240,194.36 year-on-year[16]. - Basic earnings per share were ¥2.40, which is a 400.00% increase compared to ¥0.48 in the same period last year[16]. - Total assets at the end of the reporting period amounted to ¥1,307,779,202.55, reflecting a 176.69% increase from ¥472,654,052.22 at the end of the previous year[16]. - The net assets attributable to shareholders were ¥1,114,787,725.98, up 183.78% from ¥392,837,530.01 at the end of the last year[16]. - Operating profit reached 311.78 million yuan, up 466.60% compared to the previous year[49]. - The company reported a significant increase in net profit after deducting non-recurring gains and losses, amounting to ¥255,701,033.22, a 473.00% increase from ¥44,625,298.22 in the previous year[16]. Revenue Breakdown - Revenue from infrared products amounted to ¥10,427.85 million, accounting for 17.43% of total revenue, with a year-on-year growth of 444.52%[50]. - Revenue from body temperature measurement products was ¥29,866.39 million, making up 49.93% of total revenue, and increased by 9,624.66% year-on-year[50]. - Non-epidemic product revenue was ¥19,518.90 million, accounting for 32.63% of total revenue, reflecting an 8.34% decline year-on-year[51]. - The company's revenue for the instrument manufacturing industry reached CNY 590.21 million, with a year-on-year growth of 152.87%[62]. - Sales revenue from the medical, construction, and automotive categories increased by 1,215.16% year-on-year, contributing to a gross margin of 71.50%[62]. Cash Flow and Investments - The net increase in cash and cash equivalents was ¥725,529,972.46, a remarkable increase of 1,248.44% compared to ¥53,805,038.72 in the previous year[57]. - Operating cash flow for the period was ¥276,371,725.93, a significant increase of 382.83% from ¥57,240,194.36 in the previous year[57]. - The company invested CNY 10,066,034.02 in fixed assets during the first half of 2020, compared to CNY 3,453,820.19 in the same period of 2019, marking an increase of about 191%[167]. - The net cash flow from investment activities was negative at CNY -10,066,034.02, worsening from CNY -3,453,820.19 in the previous year[167]. Market Expansion and R&D - The company is actively expanding its market presence, particularly in emerging markets like Russia and India, promoting its own brand "CEM" products[32]. - The company's research and development model is based on market research and demand analysis, ensuring effective product development aligned with market needs[28]. - Research and development expenses increased by 48.82% to ¥21,377,263.17, driven by higher salaries and material costs[57]. - The company has obtained a total of 223 domestic and international patents as of June 30, 2020, including 13 invention patents and 52 utility model patents[36]. Shareholder Information - The company plans to distribute a cash dividend of ¥9.6 per 10 shares, totaling approximately ¥128,000,000 based on 133,333,400 shares[5]. - The company reported a distributable profit of ¥358,176,297.32 for the period[94]. - The total number of shares for the cash dividend distribution is based on 133,333,400 shares[94]. - Major shareholder Yuan Jianmin holds 54.00% of the company's shares, totaling 72 million shares[130]. Risks and Challenges - The company anticipates a significant decrease in demand for infrared body temperature measurement products as the COVID-19 pandemic is brought under control, leading to uncertainty in future performance[84]. - Approximately 50% of the company's export revenue comes from the United States, exposing it to risks from ongoing US-China trade tensions[85]. - The company has a high dependency on foreign markets, with over 70% of its products sold internationally, which may be affected by changes in import regulations[86]. - Labor costs are expected to rise due to a decreasing workforce and increasing rental costs for office and production facilities[89]. Compliance and Governance - The company strictly adhered to environmental regulations and did not face any administrative penalties during the reporting period[120]. - The financial report for the first half of 2020 was not audited[146]. - The company has not reported any significant changes in the use of raised funds or major asset sales during the reporting period[79][82]. - The company did not engage in any asset or equity acquisitions or sales during the reporting period[107].

深圳市华盛昌科技实业股份有限公司 2020 年第一季度报告全文 深圳市华盛昌科技实业股份有限公司 2020 年第一季度报告 2020 年 04 月 1 深圳市华盛昌科技实业股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人袁剑敏、主管会计工作负责人金筱华及会计机构负责人(会计主 管人员)刘海琴声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市华盛昌科技实业股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 □ 适用 √ 不适用 公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益 项目界定为经常性损益的项目的情形。 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- ...